Cleo Diagnostics Ltd Stock

Cleo Diagnostics Ltd is an Australia-based medical diagnostics company. The Company is focussed on the development of non-invasive blood based In vitro diagnostics (IVD) tests to detect the presence, and recurrence, of ovarian cancer. The Company has developed a three-phased product development strategy that will deliver three related tests for ovarian cancer detection: Triage Test, Recurrence Test, and Screening Test. Triage Test is a pre-surgical test to determine the likelihood that a pre-surgical ovarian mass in a patient not yet referred to an oncologist, is malignant. Recurrence Test is a post-surgical test to identify whether a cancer is recurring following surgical removal and chemotherapy of a primary tumour. Screening Test is a screening test to identify early-stage ovarian cancer in women who do not present any symptoms consistent with ovarian cancer. The Company also offers the CLEO Test Kit, which is designed to detect a novel protein biomarker, CXCL10 in the blood.